SCHEMBL1813851

SCHEMBL1813851

N#Cc1ncc(-c2ccn[nH]2)cc1[N+](=O)[O-]

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
MEN1 O00255 1/20 0.45
MITF O75030 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
HPGDS O60760 2/20 0.39
LTA4H P09960 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NOTUM Q6P988 4/20 0.36
SCN4A P35499 1/20 0.35
PDPK1 O15530 1/20 0.35
UCHL1 P09936 1/20 0.35
CYP2E1 P05181 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2B6 P20813 1/20 0.35
CD74 P04233 1/20 0.33
MIF P14174 1/20 0.33
POLB P06746 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807875 0.78 VCAM1 (0.50) MAPTMEN1MITFHTTKMT2A
SCHEMBL1816665 0.76 NOTUM (0.53) HPGDSLTA4HNOTUMSCN4APDPK1
SCHEMBL4438379 0.76 CRHBP (0.49) MAPTMEN1KMT2ASMN1; SMN2POLB
SCHEMBL1813050 0.76 MAPT (0.47) MAPTMEN1MITFHTTKMT2A
SCHEMBL4973078 0.72 CYP2A6 (0.41) MAPTMEN1KMT2ASMN1; SMN2CYP2A6
SCHEMBL11613479 0.72 ALDH1A1 (0.47) MAPTMEN1HTTKMT2ASMN1; SMN2
SCHEMBL4554080 0.71 NOTUM (0.61) MAPTMEN1MITFHTTKMT2A
SCHEMBL128443 0.69 SMN1; SMN2 (0.50) MAPTSMN1; SMN2POLBCYP2C9HPGD
SCHEMBL3931505 0.69 VCAM1 (0.51) MAPTPOLBCYP2C9HPGDAPEX1
SCHEMBL13496371 0.69 VCAM1 (0.40) MAPTMEN1HTTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 EP disclosed
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2017-09-14 US disclosed
US-9657003-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2017-05-23 US disclosed
EP-3056485-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2016-08-17 EP disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 CN disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885MEN1 1934/4885MITF 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.